Study Number:	MOG08002B
Study Gender:	Both
PWG Approval Date	See web page for date of PWG Approval

F0 Female

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**35**	**35**	**35**	**35**
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (GD 18 - 24, LD 0 - 28, SD 24 - 27)	**35**	**35**	**35**	**35**
Number of Animals Examined	**3**	**2**		**2**
ALIMENTARY SYSTEM				
LIVER	(2)	(2)	(0)	(0)
HEPATODIAPHRAGMATIC NODULE		2 (100%)		
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
OVARY	(3)	(0)	(0)	(0)
FOLLICLE; CYST	1 (33.3%)			
UTERUS	(0)	(0)	(0)	(2)
INFLAMMATION, ACUTE				1 (50%)
PLACENTA; RETENTION				1 (50%)
HEMATOLYMPHOID SYSTEM				
None				

F0 Female

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
None				

F1 Male : Subchronic Male

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**10**	**10**	**10**	**10**
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 115 - 119)	**10**	**10**	**10**	**10**
Number of Animals Examined	**10**	**10**	**10**	**10**
Total number litters	**10**	**10**	**10**	**10**
ALIMENTARY SYSTEM				
LIVER	(10)	(0)	(2)	(10)
EXTRAMEDULLARY HEMATOPOIESIS	2 (20%) [2]			4 (40%) [4]
HEPATODIAPHRAGMATIC NODULE			2 (100%) [2]	
PANCREAS	(10)	(0)	(0)	(10)
ACINAR CELL; ATROPHY				1 (10%) [1]
CARDIOVASCULAR SYSTEM				
HEART	(10)	(0)	(0)	(10)
CARDIOMYOPATHY	4 (40%) [4]			4 (40%) [4]
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				

F1 Male : Subchronic Male

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
GENITAL SYSTEM				
EPIDIDYMIS	(10)	(10)	(10)	(10)
DUCT; EXFOLIATED GERM CELL	0 **			3 (30%) [3]
HYPOPLASIA				1 (10%) [1]
DUCT; HYPOSPERMIA				1 (10%) [1]
PENIS	(2)	(0)	(0)	(1)
DEVELOPMENTAL MALFORMATION				1 (100%) [1]
PREPUTIAL GLAND	(10)	(10)	(10)	(10)
ABSCESS	1 (10%) [1]			
DUCT; ECTASIA	2 (20%) [2]	2 (20%) [2]		2 (20%) [2]
INFLAMMATION, CHRONIC	2 (20%) [2]	4 (40%) [4]	3 (30%) [3]	
PROSTATE GLAND	(10)	(10)	(10)	(10)
HYPOPLASIA; DORSOLATERAL	0 **			10 (100%) [10] **
HYPOPLASIA; VENTRAL	0 **			10 (100%) [10] **
INFLAMMATION, CHRONIC; VENTRAL	3 (30%) [3]	5 (50%) [5]	4 (40%) [4]	4 (40%) [4]
SEMINAL VESICLE	(10)	(10)	(10)	(10)
BILATERAL; HYPOPLASIA	0 **			10 (100%) [10] **
TESTIS	(10)	(10)	(10)	(10)
GERM CELL; APOPTOSIS				1 (10%) [1]
LEYDIG CELL; ATROPHY				1 (10%) [1]
GERMINAL EPITHELIUM; DEGENERATION	0 *			2 (20%) [2]
SEMINIFEROUS TUBULE; RETENTION; SPERMATID				1 (10%) [1]
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				

F1 Male : Subchronic Male

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
KIDNEY	(10)	(0)	(0)	(10)
CHRONIC PROGRESSIVE NEPHROPATHY	10 (100%) [10]			5 (50%) [5]
CORTICOMEDULLARY JUNCTION; MINERAL				7 (70%) [7] **

F1 Female : Subchronic Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**10**	**10**	**10**	**10**
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 116 - 120)	**10**	**10**	**10**	**10**
Number of Animals Examined	**10**	**10**	**10**	**10**
Total number litters	**10**	**10**	**10**	**10**
ALIMENTARY SYSTEM				
INTESTINE, RECTUM	(10)	(0)	(0)	(10)
LYMPHOID TISSUE; HYPERPLASIA				1 (10%) [1]
LIVER	(10)	(1)	(0)	(10)
BASOPHILIC FOCUS				1 (10%) [1]
DEFORMITY		1 (100%) [1]		
HEPATODIAPHRAGMATIC NODULE	2 (20%) [2]			
PANCREAS	(10)	(0)	(0)	(10)
ACINAR CELL; ATROPHY	1 (10%) [1]			
CARDIOVASCULAR SYSTEM				
HEART	(10)	(0)	(0)	(10)
CARDIOMYOPATHY				1 (10%) [1]
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				

F1 Female : Subchronic Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
GENITAL SYSTEM				
CLITORAL GLAND	(10)	(1)	(0)	(10)
DUCT; ECTASIA	4 (40%) [4]	1 (100%) [1]		1 (10%) [1]
INFLAMMATION, CHRONIC				1 (10%) [1]
OVARY	(10)	(10)	(10)	(10)
FOLLICLE; CYST	1 (10%) [1]			2 (20%) [2]
BILATERAL; HYPOPLASIA	0 **			10 (100%) [10] **
HYPOPLASIA (UNILATERAL OR BILATERAL)	0 **			10 (100%) [10] **
UTERUS	(10)	(10)	(10)	(10)
ENDOMETRIUM; CYST	1 (10%) [1]	1 (10%) [1]	1 (10%) [1]	
DILATION; GLANDULAR			2 (20%) [2]	
DILATION; GLANDULAR, CYSTIC	0 **			6 (60%) [6] **
STROMA; HYALINIZATION	0 **			10 (100%) [10] **
HYPOPLASIA	0 **			10 (100%) [10] **
EPITHELIUM; METAPLASIA; SQUAMOUS	0 **			10 (100%) [10] **
VAGINA	(10)	(10)	(10)	(10)
MUCIFICATION		1 (10%) [1]		
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				

F1 Female : Subchronic Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
ZYMBALS GLAND	(10)	(0)	(0)	(10)
DUCT; ECTASIA	2 (20%) [2]			
URINARY SYSTEM				
KIDNEY	(10)	(0)	(0)	(10)
CHRONIC PROGRESSIVE NEPHROPATHY	6 (60%) [6]			4 (40%) [4]
INFARCT, CHRONIC; MULTIPLE				1 (10%) [1]
CORTICOMEDULLARY JUNCTION; MINERAL	9 (90%) [9]			6 (60%) [6]
NEPHROBLASTEMATOSIS	1 (10%) [1]			
URINARY BLADDER	(10)	(0)	(0)	(9)
HYPERPLASIA; UROTHELIAL				1 (11.1%) [1]

F1 Male : Prenatal Males

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**22**	**21**	**22**	**20**
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 119 - 121)	**22**	**21**	**22**	**20**
Number of Animals Examined	**7**	**3**	**2**	**20**
Total number litters	**7**	**3**	**2**	**20**
ALIMENTARY SYSTEM				
INTESTINE, COLON	(2)	(1)	(0)	(0)
LYMPHOID TISSUE; PEYERS PATCH; HYPERPLASIA		1 (100%) [1]		
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				

F1 Male : Prenatal Males

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
GENITAL SYSTEM				
COWPERS GLAND	(2)	(0)	(0)	(12)
HYPOPLASIA				12 (100%) [12]
HYPOPLASIA (UNILATERAL OR BILATERAL)				12 (100%) [12]
EPIDIDYMIS	(3)	(0)	(0)	(1)
ASPERMIA	1 (33.3%) [1]			1 (100%) [1]
LEVATOR ANI PLUS BULBOCAVERNOSUS MUSCLE	(2)	(0)	(1)	(18)
HYPOPLASIA				17 (94.4%) [17]
PREPUTIAL GLAND	(7)	(2)	(0)	(1)
ABSCESS		1 (50%) [1]		1 (100%) [1]
DUCT; ECTASIA	6 (85.7%) [6]	2 (100%) [2]		1 (100%) [1]
INFLAMMATION, ACUTE	1 (14.3%) [1]			
INFLAMMATION, CHRONIC	1 (14.3%) [1]			
PROSTATE GLAND	(2)	(0)	(0)	(18)
HYPOPLASIA; DORSOLATERAL				18 (100%) [18]
HYPOPLASIA; VENTRAL				18 (100%) [18]
INFLAMMATION, CHRONIC; VENTRAL				12 (66.7%) [12]
SEMINAL VESICLE	(2)	(1)	(1)	(19)
HYPOPLASIA		1 (100%) [1]	1 (100%) [1]	19 (100%) [19]
TESTIS	(3)	(0)	(0)	(1)
SEMINIFEROUS TUBULE; ATROPHY	1 (33.3%) [1]			1 (100%) [1]
EDEMA	1 (33.3%) [1]			
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				

F1 Male : Prenatal Males

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
None				

F1 Female : Prenatal Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**22**	**21**	**22**	**20**
Early Deaths				
Euthanized, moribund	**1**			
Unscheduled Sacrifice				**1**
Scheduled Deaths				
Scheduled sacrifice, terminal (GD 21, LD 0, PND 125 - 129)	**21**	**21**	**22**	**19**
Number of Animals Examined	**3**		**1**	**19**
Total number litters	**3**		**1**	**19**

ALIMENTARY SYSTEM
None

CARDIOVASCULAR SYSTEM
None

ENDOCRINE SYSTEM
None

GENERAL BODY SYSTEM
None

F1 Female : Prenatal Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
GENITAL SYSTEM				
OVARY	(2)	(0)	(1)	(19)
FOLLICLE; CYST			1 (100%) [1]	
HYPOPLASIA			1 (100%) [1]	19 (100%) [19]
HYPOPLASIA (UNILATERAL OR BILATERAL)			1 (100%) [1]	19 (100%) [19]
UTERUS	(0)	(0)	(1)	(19)
ENDOMETRIUM; CYST			1 (100%) [1]	4 (21.1%) [4]
HYPOPLASIA			1 (100%) [1]	19 (100%) [19]
EPITHELIUM; METAPLASIA; SQUAMOUS			1 (100%) [1]	19 (100%) [19]
EPITHELIUM; NECROSIS			1 (100%) [1]	19 (100%) [19]
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
None				

F1 Male : Fertility Males

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**22**	**24**	**21**	**20**
Early Deaths				
Found Dead		**1**		
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 152 - 154)	**22**	**23**	**21**	**20**
Number of Animals Examined	**22**	**24**	**21**	**20**
Total number litters	**22**	**24**	**21**	**20**
ALIMENTARY SYSTEM				
LIVER	(2)	(1)	(0)	(0)
HEPATODIAPHRAGMATIC NODULE		1 (100%) [1]		
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				

F1 Male : Fertility Males

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
GENITAL SYSTEM				
COAGULATING GLAND	(22)	(24)	(21)	(20)
BILATERAL; HYPOPLASIA	0 **			18 (90%) [18] **
COWPERS GLAND	(22)	(24)	(21)	(18)
BILATERAL; HYPOPLASIA	0 **			15 (83.3%) [15] **
HYPOPLASIA		1 (4.2%) [1]		
HYPOPLASIA (UNILATERAL OR BILATERAL)	0 **	1 (4.2%) [1]		15 (83.3%) [15] **
EPIDIDYMIS	(22)	(24)	(21)	(20)
ASPERMIA	1 (4.5%) [1]			
DUCT; ATROPHY	0 **			10 (50%) [10] **
DUCT; EXFOLIATED GERM CELL	0 **		1 (4.8%) [1]	5 (25%) [5] *
HYPOPLASIA				1 (5%) [1]
DUCT; HYPOSPERMIA	0 **		1 (4.8%) [1]	6 (30%) [6] **
LEVATOR ANI PLUS BULBOCAVERNOSUS MUSCLE	(22)	(24)	(21)	(20)
HYPOPLASIA	0 **		1 (4.8%) [1]	17 (85%) [17] **
PENIS, GLANS	(0)	(0)	(0)	(1)
DEVELOPMENTAL MALFORMATION				1 (100%) [1]
PREPUTIAL GLAND	(22)	(24)	(21)	(20)
ABSCESS	5 (22.7%) [5]	3 (12.5%) [3]		
DUCT; ECTASIA	7 (31.8%) [7]	15 (62.5%) [15] *	12 (57.1%) [12]	6 (30%) [6]
INFLAMMATION, CHRONIC	7 (31.8%) [7]	8 (33.3%) [8]	9 (42.9%) [9]	6 (30%) [6]
PROSTATE GLAND	(22)	(24)	(21)	(20)
HYPOPLASIA; DORSOLATERAL	0 **			18 (90%) [18] **
HYPOPLASIA; VENTRAL	0 **			18 (90%) [18] **
INFLAMMATION, CHRONIC; VENTRAL	9 (40.9%) [9]	6 (25%) [6]	6 (28.6%) [6]	6 (30%) [6]
SEMINAL VESICLE	(22)	(24)	(21)	(20)
BILATERAL; HYPOPLASIA	0 **			18 (90%) [18] **
TESTIS	(22)	(24)	(21)	(20)

F1 Male : Fertility Males

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
GERM CELL; APOPTOSIS				1 (5%) [1]
LEYDIG CELL; ATROPHY	0 **			11 (55%) [11] **
SEMINIFEROUS TUBULE; ATROPHY	1 (4.5%) [1]			
GERMINAL EPITHELIUM; DEGENERATION	0 **		1 (4.8%) [1]	6 (30%) [6] **
INTERSTITIAL CELL; HYPERPLASIA	1 (4.5%) [1]			
HYPOPLASIA				1 (5%) [1]
SEMINIFEROUS TUBULE; RETENTION; SPERMATID	0 **			8 (40%) [8] **
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
None				

F1 Female : Fertility Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**22**	**24**	**21**	**20**
Early Deaths				
Unscheduled Sacrifice				**1**
Scheduled Deaths				
Scheduled sacrifice, terminal (GD 46 - 50, LD 26 - 28, PND 158 - 162)	**22**	**24**	**21**	**19**
Number of Animals Examined	**22**	**24**	**21**	**20**
Total number litters	**22**	**24**	**21**	**20**
ALIMENTARY SYSTEM				
None				
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				

F1 Female : Fertility Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
GENITAL SYSTEM				
CERVIX	(22)	(24)	(21)	(20)
CYST; SQUAMOUS	1 (4.5%) [1]		1 (4.8%) [1]	1 (5%) [1]
INFLAMMATION, ACUTE				1 (5%) [1]
OVARY	(22)	(24)	(21)	(20)
FOLLICLE; CYST	2 (9.1%) [2]		1 (4.8%) [1]	
BILATERAL; HYPOPLASIA	0 **	1 (4.2%) [1]		20 (100%) [20] **
HYPOPLASIA		2 (8.3%) [2]		
HYPOPLASIA (UNILATERAL OR BILATERAL)	0 **	3 (12.5%) [3]		20 (100%) [20] **
UTERUS	(22)	(24)	(21)	(20)
EPITHELIUM; APOPTOSIS; INCREASED	0 *		1 (4.8%) [1]	3 (15%) [3]
CERVIX; CYST			1 (4.8%) [1]	
DECIDUAL REACTION	1 (4.5%) [1]			
DILATION; GLANDULAR	2 (9.1%) [2]			
DILATION; GLANDULAR, CYSTIC	0 **			8 (40%) [8] **
DILATION		1 (4.2%) [1]		
STROMA; HYALINIZATION	0 **		8 (38.1%) [8] **	18 (90%) [18] **
HYPOPLASIA	0 **			18 (90%) [18] **
CERVIX; INFLAMMATION, ACUTE				1 (5%) [1]
INFLAMMATION, ACUTE				1 (5%) [1]
EPITHELIUM; METAPLASIA; SQUAMOUS	0 **			20 (100%) [20] **
POLYP STROMAL			1 (4.8%) [1]	
VAGINA	(22)	(24)	(21)	(20)
CYST	1 (4.5%) [1]			
DEVELOPMENTAL MALFORMATION				1 (5%) [1]
HEMATOLYMPHOID SYSTEM				
None				

F1 Female : Fertility Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
None				

F1 Male : F1 Extra Males

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**21**	**46**	**46**	**40**
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 28)	**21**	**46**	**46**	**40**
Number of Animals Examined	**3**		**8**	**20**
Total number litters	**2**		**5**	**9**
ALIMENTARY SYSTEM				
None				
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
EPIDIDYMIS	(2)	(0)	(8)	(17)
BILATERAL; IMMATURE			8 (100%) [5]	16 (94.1%) [7]
IMMATURE				1 (5.9%) [1]
IMMATURE (UNILATERAL OR BILATERAL)			8 (100%) [5]	17 (100%) [7]
TESTIS	(2)	(0)	(8)	(20)
BILATERAL; IMMATURE			8 (100%) [5]	17 (85%) [8]
IMMATURE				3 (15%) [2]
IMMATURE (UNILATERAL OR BILATERAL)			8 (100%) [5]	20 (100%) [9]

F1 Male : F1 Extra Males

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
KIDNEY	(2)	(0)	(0)	(0)
PELVIS; DILATION	1 (50%) [1]			

F1 Female : F1 Extra Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**45**	**29**	**48**	**17**
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 28)	**45**	**29**	**48**	**17**
Number of Animals Examined	**1**			
Total number litters	**1**			
ALIMENTARY SYSTEM				
None				
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
None				
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				

F1 Female : F1 Extra Females

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
None				

F1 Male : PND28 Bio&MGWM Male

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**12**	**12**	**12**	**12**
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 28)	**12**	**12**	**12**	**12**
Number of Animals Examined			**1**	**3**
Total number litters			**1**	**3**
ALIMENTARY SYSTEM				
None				
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
EPIDIDYMIS	(0)	(0)	(0)	(3)
BILATERAL; IMMATURE				3 (100%) [3]
IMMATURE (UNILATERAL OR BILATERAL)				3 (100%) [3]
TESTIS	(0)	(0)	(1)	(3)
BILATERAL; IMMATURE				3 (100%) [3]
IMMATURE			1 (100%) [1]	
IMMATURE (UNILATERAL OR BILATERAL)			1 (100%) [1]	3 (100%) [3]

F1 Male : PND28 Bio&MGWM Male

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
None				

F1 Female : Bio&MGWM @ VO

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
Disposition Summary				
Animals Initially In Study	**12**	**12**	**12**	**12**
Early Deaths				
Unscheduled Sacrifice				**1**
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 26 - 39)	**12**	**12**	**12**	**11**
Number of Animals Examined	**12**	**12**	**12**	**12**
Total number litters	**12**	**11**	**9**	**12**
ALIMENTARY SYSTEM				
None				
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				

F1 Female : Bio&MGWM @ VO

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
GENITAL SYSTEM				
OVARY	(12)	(12)	(12)	(12)
HYPOPLASIA			1 (8.3%) [1]	
HYPOPLASIA (UNILATERAL OR BILATERAL)			1 (8.3%) [1]	
INFLAMMATION, ACUTE				1 (8.3%) [1]
OVIDUCT	(0)	(0)	(0)	(1)
INFLAMMATION, ACUTE				1 (100%) [1]
UTERUS	(2)	(0)	(0)	(1)
INFLAMMATION, ACUTE				1 (100%) [1]
VAGINA	(2)	(0)	(0)	(1)
DEVELOPMENTAL MALFORMATION				1 (100%) [1]
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				

F1 Female : Bio&MGWM @ VO

	Treatment Groups (ppm)			
	0	**338**	**1125**	**3750**
URINARY SYSTEM				
None				

LEGEND

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number of animals with observation reported with percent incidence in parentheses

Number of litters with observations shown in square brackets for F1 and F2 animals. F1 litter incidence based on the number of F0 dams; F2 litter incidence based on number of F1 dams.

Statistical analysis performed by Cochran-Armitage test with poly-3 adjustment for both trend and pairwise tests for cohorts where all organs were fully examined. This included F1 subchronic (all organs), F1 Fertility (reproductive organs), and F1 Bio&MGWM@VO (ovaries only).

For the F0, F1 Prenatal, and F1 Extra cohorts, histopathology was limited to gross lesions only, so no statistical testing was performed.

All trend and pairwise p-values are reported as one-sided.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

Non-pregnant females from the F0 and F1 generations are included in the analysis.

SD – Study Day; GD – Gestation Day; LD – Lactation Day; PND – Postnatal Day, adults post-weaning

** END OF REPORT **